Neue abgeschwächte Pseudomonas-Aeruginosa-Stämme

The present invention relates to novel safe attenuated Pseudomonas aeruginosa strains obtained by isolating Pseudomonas aeruginosa in a pure state according to Fisher-Devlin immunotype and then repeatedly purifying the isolated strain, particularly CFCPA 10142 (KCCM 10029), CFCPA 20215 (KCCM 10030),...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	PARK, WAN JE, SUWON, KR, LEE, DONG EOK, SEOUL/SOUL, KR, YOO, REE AN, KWACHUN, KR, KIM, DAL HYUN, SUWON, KR, MOON, MOO SANG, SEOUL/SOUL, KR, KIM, HYUN SU, SEOUL/SOUL, KR, HA, SUK HOON, SEOUL/SOUL, KR, HONG, SUN PYO, SEOUL/SOUL, KR, YOO, WANG DON, SEOUL/SOUL, KR, NOH, KAP SOO, SEOUL/SOUL, KR, KIM, YOUNG GI, SEOUL/SOUL, KR, CHO, YANG JE, SEOUL/SOUL, KR, KIM, JE HAK, KWACHUN, KR, LEE, NAM JOONG, SEOUL/SOUL, KR
Format:	Patent
Sprache:	ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to novel safe attenuated Pseudomonas aeruginosa strains obtained by isolating Pseudomonas aeruginosa in a pure state according to Fisher-Devlin immunotype and then repeatedly purifying the isolated strain, particularly CFCPA 10142 (KCCM 10029), CFCPA 20215 (KCCM 10030), CFCPA 30720 (KCCM 10031), CFCPA 40057 (KCCM 10032), CFCPA 50243 (KCCM 10033), CFCPA 60534 (KCCM 10034) and CFCPA 70018 (KCCM 10035) strains. In addition the present invention relates to a vaccine for immunization against Pseudomonas aeruginosa infection which includes cell wall proteins having molecular weight ranging from 10,000 to 100,000, obtained from the attenuated Pseudomonas aeruginosa strains, a therapeutic agent for treating Pseudomonas aeruginosa infection containing immunoglobulin(s) induced by the cell wall proteins in an experimental animal, and methods of their preparation. The cell wall protein component of the attenuated strain is non-pathogenic and safe and exhibits excellent antibody formation and is useful for preparation of a vaccine and therapeutic agent. The cell wall proteins exhibit an excellent cross-protective capacity for various Pseudomonas aeruginosa strains and a superior antibody inducing property.